Investor Overview Press Releases January 9, 2020 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor January 8, 2020 Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors November 12, 2019 Aclaris Therapeutics to Present at Upcoming Investor Conferences View all » Events Dec 4, 20193:05 PM EST Aclaris Therapeutics, Inc. at Evercore ISI 2nd Annual HealthCONx Conference Nov 7, 20195:00 PM EST Q3 2019 Aclaris Therapeutics Inc. Earnings Conference Call Oct 24, 20194:30 PM EDT Aclaris Therapeutics Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-1) View all » Feature presentation More presentations coming soon.
January 9, 2020 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
Oct 24, 20194:30 PM EDT Aclaris Therapeutics Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-1)
